A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation
Metadata only so far. Questions are answered only with quotes from this document. Source: ctgov, ctgov, retrieved 2026-11-02.
Ongoing
Record metadata
- Phase
- Phase 2
- Status
- Recruiting
- Start
- 2026-08-20
- End
- 2029-08-31
- Enrollment
- 120
- Sites
- 1
- Sponsor class
- INDUSTRY
Not in the data yet: a trial card. Cards (population, design, endpoints, result direction, each tied to a quote) arrive with the knowledge layer’s card lane. The fields above are registry or bibliographic metadata, not quotes.
Ask this document
Answers come only from this document’s licensed passages, as highlighted quotes. If it doesn’t say, you get that instead of a guess.
Source text
No passages are loaded for this document yet.